Pharmacogenetics of EGFR and VEGF inhibition.
作者： Jan Pander , Hans Gelderblom , Henk-Jan Guchelaar
DOI: 10.1016/J.DRUDIS.2007.10.016
关键词:
摘要: Even though treatment of several types solid tumours has improved in the past few years with introduction monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial (VEGF), response rates to these targeted therapies are modest. Pharmacogenetic factors have potential select patients higher chance agents that target pathways. This review provides an overview over germ-line variations genes potentially involved pharmacodynamics cetuximab, panitumumab bevacizumab, which may underlie variable anti-tumour response.
elsevier.com
csmres.co.uk 参考文章(66)
Sébastien Dall’Ozzo, Sophie Tartas, Gilles Paintaud, Guillaume Cartron, Philippe Colombat, Pierre Bardos, Hervé Watier, Gilles Thibault, Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Research. ,vol. 64, pp. 4664- 4669 ,(2004) , 10.1158/0008-5472.CAN-03-2862
Wen-Kai Weng, Ronald Levy, Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma Journal of Clinical Oncology. ,vol. 21, pp. 3940- 3947 ,(2003) , 10.1200/JCO.2003.05.013
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Xinyu S. Fu, Eunis Choi, Glenn J. Bubley, Steven P. Balk, Identification of hypoxia-inducible factor-1α (HIF-1α) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation The Prostate. ,vol. 63, pp. 215- 221 ,(2005) , 10.1002/PROS.20190
Hidehiko Kariyazono, Takuro Ohno, Vahid Khajoee, Kenji Ihara, Koichi Kusuhara, Naoko Kinukawa, Yumi Mizuno, Toshiro Hara, Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatric Research. ,vol. 56, pp. 953- 959 ,(2004) , 10.1203/01.PDR.0000145280.26284.B9
E. Louis, Z. El Ghoul, S. Vermeire, S. Dall'Ozzo, P. Rutgeerts, G. Paintaud, J. Belaiche, M. De Vos, A. Van Gossum, J. -F. Colombel, H. Watier, Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease Alimentary Pharmacology & Therapeutics. ,vol. 19, pp. 511- 519 ,(2004) , 10.1111/J.1365-2036.2004.01871.X
Michael I. Koukourakis, Dimitrios Papazoglou, Alexandra Giatromanolaki, Ioannis Panagopoulos, Efstratios Maltezos, Adrian L. Harris, Kevin C. Gatter, Efthimios Sivridis, C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1α gene define HIF-1α protein expression in non-small cell lung cancer Lung Cancer. ,vol. 53, pp. 257- 262 ,(2006) , 10.1016/J.LUNGCAN.2006.05.025
Ulrich J. H. Sachs, Ines Socher, Christian G. Braeunlich, Hartmut Kroll, Gregor Bein, Sentot Santoso, A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α‐chain promoter Immunology. ,vol. 119, pp. 83- 89 ,(2006) , 10.1111/J.1365-2567.2006.02408.X
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Sae-Won Han, Yoon Kyung Jeon, Kyung-Hun Lee, Bhumsuk Keam, Pil Gyu Hwang, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Dae Seog Heo, Yung-Jue Bang, Tae-You Kim, None, Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenetics and Genomics. ,vol. 17, pp. 313- 319 ,(2007) , 10.1097/FPC.0B013E328011ABC0